New drugs in type 2 diabetes mellitus therapy

Česká verzia

Authors: M. Kvapil
Authors place of work: Interní klinika 2. lékařské fakulty UK a FN Motol Praha, přednosta prof. MU Dr. Milan Kvapil, CSc., MBA
Published in the journal: Vnitř Lék 2013; 59(8): 713-718
Category:

Summary

The objective in developing a new type 2 diabetes therapy is to achieve greater safety and better efficacy. Newly registered drugs include lixisenatide, QW exenatide, dapagliflozin and insulin degludec. Once weekly gliptins and other substances are under development.

Key words:
type 2 diabetes mellitus therapy – gliptins – exenatide – lixisenatide – insulin degludec – dapagliflozin

Zdroje

1. Monami M, Dicembrini I, Martelli D et al. Safety of dipeptidyl peptidase‑ 4 inhibitors: a meta‑analysis of randomized clinical trials. Curr Med Res Opin 2011; 27 (Suppl 3): 57– 64.

2. Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase‑ 4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta‑analysis. Diabetes Obes Metab 2012; 14: 1061– 1072.

3. Park H, Park C, Kim Y et al. Efficacy and safety of dipeptidyl peptidase‑ 4 inhibitors in type 2 diabetes: meta‑analysis. Ann Pharmacother 2012; 46: 1453– 1469.

4. Vilsbøll T, Rosenstock J, Yki‑ Järvinen H et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 167– 177.

5. Rizos EC, Ntzani EE, Papanas N et al. Combination Therapies of DPP4 Inhibitors and GLP1 Analogues with Insulin in Type 2 Diabetic Patients: A Systematic Review. Curr Vasc Pharmacol 2012. In press.

6. Kvapil M. Léčba kombinací bazálního inzulínu a inkretinové terapie. In: Kvapil M (ed). Diabetologie 2013. Praha: Triton 2012: 163– 169.

7. Jose T, Inzucchi SE. Cardiovascular effects of the DPP‑ 4 inhibitors. Diab Vasc Dis Res 2012; 9: 109– 116.

8. Theiss HD, Brenner C, Engelmann MG et al. Safety and efficacy of SITAgliptin plus GRanulocyte‑ colony‑ stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI‑ Trial) – rationale, design and first interim analysis. Int J Cardiol 2010; 145: 282– 284.

9. Kvapil M. Sitagliptin pro rok 2013. In: Kvapil M (ed). Diabetologie 2013. Praha: Triton 2013: 147– 157.

10. Gantz I, Chen M, Mirza A et al. Effect of MK‑ 3102, a novel once‑weekly DPP‑ 4 inhibitor, over 12‑weeks in patients with type 2 diabetes mellitus. Diabetologia 2012; 55 (Suppl 1): S51.

11. http:/ / clinicaltrials.gov/ ct2/ results?term=MK‑ 3102&Search=Search.

12. Engel SS, Golm GT, Shapiro D et al. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol 2013; 12: 3.

13. Elkinson S, Keating GM. Lixisenatide: first global approval. Drugs 2013; 73: 383– 391.

14. Ahrén B. Gut peptides and Type 2 diabetes mellitus treatment. Curr Diab Rep 2003; 3: 365– 372.

15. Perušičová J, Haladová I, Piťhová P et al.Změny hmotnosti a kompenzace diabetu (HbA1c) u nemocných s diabetes mellitus 2. typu po přidání exenatidu (Byetta) ke stávající léčbě ve 28 diabetologických ambulancích v ČR – studie BIBY‑ I (sledování 3 až 12 měsíců). Vnitř Lék 2013; 59: 165– 171.

16. Perušičová J, Piťhová P, Haladová I et al. Změny hmotnosti a kompenzace diabetu (HbA1c) u nemocných s diabetes mellitus 2. typu po přidání exenatidu (Byetta) ke stávající léčbě ve 28 diabetologických ambulancích v ČR – studie BIBY‑ II (sledování 24 měsíců). Vnitř Lék 2013; 59: 249– 255.

17. Scott LJ. Exenatide extended‑ release: a review of its use in type 2 diabetes mellitus. Drugs 2012; 72: 1679– 1707.

18. Murphy CE. Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2012; 46: 812– 821.

19. Best JH, Boye KS, Rubin RR et al. Improved treatment satisfaction and weight‑related quality of life with exenatide once weekly or twice daily. Diabet Med 2009; 26: 722– 728.

20. Diamant M, Van Gaal L, Stranks S et al. Safety and efficacy of once‑weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care 2012; 35: 683– 689.

21. Fineman MS, Mace KF, Diamant M et al. Clinical relevance of anti‑exenatide antibodies: safety, efficacy and cross‑ reactivity with long‑term treatment. Diabetes Obes Metab 2012; 14: 546– 554.

22. Ratner RE, Rosenstock J, Boka G. DRI6012 Study Investigators. Dose‑dependent effects of the once‑ daily GLP‑1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double‑blind, placebo‑ controlled trial. Diabet Med 2010; 27: 1024– 1032.

23. Horowitz M, Rayner CK, Jones KL. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes. Adv Ther 2013; 30: 81– 101.

24. Kapitza C, Forst T, Coester HV et al. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab 2013; 15: 642– 649.

25. Riddle MC, Forst T, Aronson R et al. Adding Once‑ Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine: A 24- Week, Randomized, Placebo‑ Controlled Study (GetGoal‑ Duo 1). Diabetes Care 2013. In press.

26. Rosenstock J, Raccah D, Koranyi L et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in patients with T2DM insufficiently controlled on metformin (GetGoal‑ X). Poster presented at: 47th Annual Meet-ing of the EASD, September 12.– 16. 2011, Lisbon. Diabetologia 2011; 54 (Suppl 1): 1– 42. Abstract 786.

27. Fonseca VA, Alvarado‑ Ruiz R, Raccah D et al. Efficacy and safety of the once‑ daily GLP‑1 receptor agonist lixisenatide in monotherapy: a randomized, double‑blind, placebo‑ controlled trial in patients with type 2 diabetes (GetGoal‑ Mono). Diabetes Care 2012; 35: 1225– 1231.

28. Jonassen I, Havelund S, Hoeg‑ Jensen T et al. Design of the novel protraction mechanism of insulin degludec, an ultra‑ long‑acting basal insulin. Pharm Res 2012; 29: 2104– 2114.

29. Heller S, Buse J, Fisher M et al. Insulin degludec, an ultra‑ longacting basal insulin, versus insulin glargine in basal‑ bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal‑ Bolus Type 1): a phase 3, randomised, open‑ lable, treat‑ to target non‑inferiority trial. Lancet 2012; 379: 1489– 1497.

30. Birkeland KI, Home PD, Wendish U et al. Insulin degludec in type 1 diabetes. A randomized controlled trial of a new‑generation ultra‑ long‑acting insulin compared with insulin glargin. Diabetes Care 2011; 34: 661– 665.

31. Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 2003; 89: 3– 9.

32. Clar C, Gill JA, Court R et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012; 18: 2.

33. Abdul‑ Ghani MA, Norton L, DeFronzo RA. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr Diab Rep 2012; 12: 230– 238.

34. Anderson SL, Marrs JC. Dapagliflozin for the treatment of type 2 diabetes. Ann Pharmacother 2012; 46: 590– 598.

35. Nauck MA, Del Prato S, Meier JJ et al. Dapagliflozin versus glipizide as add‑ on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52‑week, double‑blind, active‑ controlled noninferiority trial. Diabetes Care 2011; 34: 2015– 2022.

36. Bolinder J, Ljunggren O, Kullberg J et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020– 1031.

37. Musso G, Gambino R, Cassader M et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co‑ transport (SGLT) inhibitors: systematic review and meta‑analysis of randomized trials. Ann Med 2012; 44: 375– 393.

38. Kvapil M. Glifloziny: inhibitory SGLT2. In: Kvapil M (ed). Diabetologie 2013. Praha: Triton 2013: 177– 184.

39. Polidori D, Sha S, Mudaliar S et al. Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo‑ controlled study. Diabetes Care 2013. In press.

40. Charbonnel B. PPAR‑alpha and PPAR‑gam-ma agonists for type 2 diabetes. Lancet 2009; 374: 96– 98.

41. Cavender MA, Lincoff AM. Therapeutic potential of aleglitazar, a new dual PPAR‑a/ g agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs 2010; 10: 209– 216.

42. Cariou B, Zaïr Y, Staels B et al. Effects of the new dual PPAR a/ d agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011; 34: 2008– 2014.

43. Šimůnková K, Hampl R, Hill M et al. Adrenocortical function in young adults with diabetes mellitus type 1. J Steroid Biochem Mol Biol 2010; 122: 35– 41.

44. Vondra K, Topolčan O, Janíčková‑ Ždárská D.Stane se vitamin D novým antidiabetikem? Vnitř Lék 2012; 58: 411– 416.

45. Raskin P, Heller S, Honka M et al. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial. Diabetes Obes Metab 2012; 14: 163– 173.